JAC Advance Access originally published online on July 1, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(2):306-310; doi:10.1093/jac/dkh340
JAC vol.54 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
The 2003 Garrod Lecture |
The relentless rise of resistance?
City Hospital, Birmingham, UK
* Email: r.wise{at}bham.ac.uk
Antibiotics have undoubtedly made a major contribution to improvements in both human and animal health and welfare. Recent years have brought alarming rises in the prevalence of resistance to some agents among certain groups of bacteria. Concern is growing that therapeutic options will become increasingly limited if resistance rates continue to rise. There is widespread agreement that action is required to reverse or at least slow this process. Necessary steps to manage the situation include better surveillance to assess accurately the extent of problems, more prudent use of the available antibiotics to conserve valuable therapeutic resources and improved infection control to limit the spread of resistant organisms. Achieving these goals will not be possible without government, the medical profession and the public being better informed and educated. Regulatory bodies and the pharmaceutical industry need to work together to ensure a steady supply of new antimicrobials. Our understanding of the processes driving resistance at both the molecular and population levels is advancing. However, the relative contributions of the various uses of antimicrobials to the resistance problem and which will be the most effective containment measures are still hotly debated. Progress is being made, but continued concerted action is necessary if the usefulness of this most important group of therapeutic agents is to be preserved.
Keywords: antibacterials , resistance , health
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Smeets, M. Kuyvenhoven, A. Akkerman, I Welschen, G. Schouten, G. van Essen, and T. Verheij Intervention with educational outreach at large scale to reduce antibiotics for respiratory tract infections: a controlled before and after study Fam. Pract., June 1, 2009; 26(3): 183 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Lu and J. J. Collins Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy PNAS, March 24, 2009; 106(12): 4629 - 4634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Y. Ong, M. M. Kuyvenhoven, L. van Dijk, and T. J. M. Verheij Antibiotics for respiratory, ear and urinary tract disorders and consistency among GPs J. Antimicrob. Chemother., September 1, 2008; 62(3): 587 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Warburton, R. M. Palmer, M. A. Munson, and W. G. Wade Demonstration of in vivo transfer of doxycycline resistance mediated by a novel transposon J. Antimicrob. Chemother., November 1, 2007; 60(5): 973 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. B. Sandrini, O. Shannon, A. R. Clausen, L. Bjorck, and J. Piskur Deoxyribonucleoside Kinases Activate Nucleoside Antibiotics in Severely Pathogenic Bacteria Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2726 - 2732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hillier, Z. Roberts, F. Dunstan, C. Butler, A. Howard, and S. Palmer Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study J. Antimicrob. Chemother., July 1, 2007; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J Soulsby Resistance to antimicrobials in humans and animals BMJ, November 26, 2005; 331(7527): 1219 - 1220. [Full Text] [PDF]
|
|
|
|
|
|
A. E. Akkerman, M. M. Kuyvenhoven, J. C. van der Wouden, and T. J. M. Verheij Analysis of under- and overprescribing of antibiotics in acute otitis media in general practice J. Antimicrob. Chemother., September 1, 2005; 56(3): 569 - 574. [Abstract] [Full Text] [PDF]
|
|